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Abstract
Purpose To evaluate the frequency of missed cancers on breast MRI in women participating in a high-risk screening program.
Methods Patient files from women who participated in an increased risk mammography and MRI screening program 
(2003–2014) were coupled to the Dutch National Cancer Registry. For each cancer detected, we determined whether an 
MRI scan was available (0–24 months before cancer detection), which was reported to be negative. These negative MRI 
scans were in consensus re-evaluated by two dedicated breast radiologists, with knowledge of the cancer location. Cancers 
were scored as invisible, minimal sign, or visible. Additionally, BI-RADS scores, background parenchymal enhancement, 
and image quality (IQ; perfect, sufficient, bad) were determined. Results were stratified by detection mode (mammography, 
MRI, interval cancers, or cancers in prophylactic mastectomies) and patient characteristics (presence of BRCA mutation, 
age, menopausal state).
Results Negative prior MRI scans were available for 131 breast cancers. Overall 31% of cancers were visible at the initially 
negative MRI scan and 34% of cancers showed a minimal sign. The presence of a BRCA mutation strongly reduced the 
likelihood of visible findings in the last negative MRI (19 vs. 46%, P < 0.001). Less than perfect IQ increased the likelihood 
of visible findings and minimal signs in the negative MRI (P = 0.021).
Conclusion This study shows that almost one-third of cancers detected in a high-risk screening program are already visible 
at the last negative MRI scan, and even more in women without BRCA mutations. Regular auditing and double reading for 
breast MRI screening is warranted.
Keywords Breast cancer · Breast MRI · High-risk screening · Prior MRI scan · Visibility
Introduction
Breast magnetic resonance imaging (MRI) is recognized as 
the most sensitive imaging method for the early detection 
of breast cancer [1]. Therefore, women at a lifetime risk for 
breast cancer development of ≥ 20% are invited for inten-
sified screening programs including both mammography 
and breast MRI. Recent prospective studies have reported 
a sensitivity of MRI of around 90% using these screening 
settings [1–5].
Studies investigating the performance of mammography 
screening programs have consistently shown that between 
31 and 50% of cancers detected in follow-up could have 
been detected at an earlier screening round [6–9]. This is one 
reason for the implementation of double reading in mam-
mography screening [10, 11]. Furthermore, the frequency 
of these errors in mammography screening is nowadays 
regularly audited.
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Although recently auditing guidelines for breast MRI 
screening were published by the American college of radi-
ology [12], these do not include the evaluation of prior 
screening rounds in women who present with breast can-
cer. A few studies that focused on reasons and features of 
missed cancers in MRI screening showed that between 47 
and 56% of cancers could have been detected at an earlier 
MRI examination [13, 14]. However, to our knowledge, no 
studies report on the visibility of interval cancers, tumors 
detected on mammography, or tumors in prophylactic mas-
tectomy specimen in the prior MRI scans.
Therefore, the purpose is to evaluate the frequency of 
visible breast cancers detected in women participating in 
a high-risk screening program, that were missed on a prior 
MRI scan (screen-detected, interval, and cancers in pro-
phylactic mastectomy specimen), and to assess patient and 
imaging factors contributing to non-detection.
Materials and methods
Ethics
The local institutional review board approved this study and 
the requirement for informed consent was waived.
Breast cancer screening in women 
at intermediate‑to‑high risk for breast cancer
The breast cancer screening program for women at high or 
intermediate risk (≥ 20–25% lifetime risk) at our institu-
tion consists of annual breast MRI and mammography, usu-
ally at the same day, although some women opt for having 
the examinations 6 months apart. In women with germline 
BRCA mutations, screening starts from the age of 25 years, 
and the first 5 years no mammography is performed. In other 
women at increased risk for breast cancer, screening starts 
from the age of 35 or 45.
All women underwent contrast-enhanced breast MRI in 
prone position using a dedicated breast coil on a 1.5- or 
3-T MRI scanner (Siemens, Erlangen, Germany). Contrast 
(Gd-DOTA, Guerbet, France) was administered through an 
iv-canula in the cubital vein at a dose of 0.1 mmol/kg using 
a power injector (Warrendale, Medrad, PA). Acquisition 
parameters changed over time, and are reported in detail 
elsewhere [15]. All MRI scans contained a 3D T1-weighted 
sequence that was performed before and 4–5 times after 
contrast administration. Clinical reporting was done by one 
of eight board-certified breast radiologists with between 
6 months and 23 years of experience in breast MRI using a 
dedicated breast MRI workstation (versions of DynaCAD, 
Philips, Best, the Netherlands), that automatically yields 
subtraction images, maximum intensity projections (MIPs), 
and enhancement curves. All mammograms were obtained 
on full-field digital mammography machines (Senograph 
DS, Senograph 2000, GE, USA) by dedicated mammogra-
phy technicians. Mammography was always performed in 
two planes (medio-lateral oblique and cranio-caudal), with 
optional further acquisitions. Clinical reporting using dedi-
cated mammography monitors was done by the radiologists 
who also reported the MRI scan.
Case selection
All screening breast MRI and mammography exams per-
formed from 01 January 2003 to 01 January 2014 were 
identified by a cross-computer search. This yielded 9571 
screening MRI studies and 6553 mammograms obtained 
in 2773 women. This database was linked to the nation-
wide population-based Netherlands Cancer Registry. In our 
cohort, 164 women presented with a total of 179 cancers. 
For these women, we noted age, menopausal status, and the 
reason for intensified screening: BRCA1, BRCA2, family his-
tory of breast cancer, personal history of breast cancer, or 
other (including germline PTEN mutation, previous radia-
tion to the chest, hormone replacement therapy, and lobular 
carcinoma in situ in an earlier biopsy).
Cancers (invasive cancers or ductal carcinoma in situ 
(DCIS)) were subsequently categorized into MRI-detected, 
mammography-detected, interval cancers, and cancers 
detected in prophylactic mastectomy specimen (further 
referred to as incidental cancers). For each of these catego-
ries, we obtained the images acquired at the time of tumor 
detection and the last MRI reported to be negative. The time 
between cancer diagnosis and the last negative MRI scan 
was recorded. When no prior negative MRI was available, 
the case was excluded (N = 48).
MRI‑detected cancers
Cancers were considered MRI-detected when they were 
screen-detected and mentioned in the MRI report at the 
time of diagnosis (hereafter called the current MRI). The 
most recent breast MRI scan reported to be negative between 
6 and 24 months before cancer diagnosis was selected for 
re-evaluation.
Mammography‑detected cancers
Cancers were considered mammography-detected when 
they were screen-detected and described in the mammog-
raphy report, but the MRI report was negative. In this 
case, the MRI performed within the same screening round 
as the mammogram was re-evaluated, and therefore, the 
time between detection and the last negative MRI scan is 
negligible.
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Interval cancers
Interval cancers were defined as cancers that were detected 
in between screening rounds due to symptoms. The last MRI 
prior to the cancer detection was selected.
Incidental cancers
Incidental cancers were defined as cancers detected in pro-
phylactic mastectomy specimens with negative prior imag-
ing. We selected the last MRI scan prior to the prophylactic 
mastectomy for assessment.
Retrospective MRI interpretation
The last negative breast MR images were re-evaluated in 
consensus by two breast radiologists with respectively 8 
and 12 years of experience in breast MRI. Readers were 
informed of the cancer location on the positive MRI and/
or the histopathology results. In the case of mammography-
detected cancers, location described in the mammography 
report and histopathology results were given.
The review was performed on an in-house developed 
dedicated breast MRI workstation [16]. The workstation 
performed motion correction [17], and showed T1-weighted 
images, subtraction images, and MIPs for all time points. 
The average contrast enhancement versus time curve was 
shown for the pointer location. For the MRI-detected cases, 
the current MRI was displayed alongside the prior MRI.
The readers, in consensus, scored whether the cancer was 
either invisible, if there was a minimal sign, or the cancer 
was visible in the last negative MRI in analogy to the Dutch 
auditing practice for mammography screening [7]. When the 
MRI was truly negative, the cancer was rated as invisible. 
Minimal signs were visible lesions at the site of the later 
detected cancer that, according to the consensus reading, 
would not likely be recalled in screening practice. Visible 
lesions were lesions that were present at the site of the later 
detected cancer and should have been recalled according to 
the consensus reading. All lesions in the current MRI, as 
well as all lesions visible or showing a minimal sign in the 
prior MRI, were assessed according to the Breast Imaging 
Reporting and Data (BI-RADS) MR-lexicon and BI-RADS 
scores were given accordingly [12, 18].
For each MRI scan, background parenchymal enhance-
ment (BPE) was scored as minimal, mild, moderate, or 
marked. In addition, image quality (IQ) was subjectively 
scored as perfect, sufficient, or bad.
Performance measures
We first assessed the frequency of visible findings and min-
imal signs in the negative MRI scans, overall and in the 
subgroups (MRI-detected, mammography-detected, interval 
cancers, and incidental cancers). Subsequently, we investi-
gated whether patient factors (age at cancer detection, meno-
pausal state, presence of a BRCA mutation) and imaging fac-
tors (field strength of MRI scanner, BPE, reported IQ) were 
related to the likelihood of missed lesions in prior breast 
MRI scans. For statistical analysis, we used Pearson’s Chi 
square tests for categorical variables and one-way ANOVA 
for continuous variables. The Tukey post-hoc test was used 
to compare the differences between the groups in case of 
continuous variables. To assess correlations, Spearman’s rho 
was computed for ordinal values and when data were not 
normally distributed (time between scan and cancer detec-
tion). A two-sided P value of ≤ 0.05 was considered statisti-
cally significant. All statistics were performed in SPSS (v22, 
SPSS Inc., Chicago, IL).
Results
Between 01 January 2003 and 01 January 2014, 131 breast 
cancers were detected in women participating in the interme-
diate- and high-risk screening program, for whom a prior (or 
in case of mammography-detected cancers current) negative 
MRI scan was available (Table 1). Of these cancers, 76 were 
MRI-detected, 13 mammography-detected, 16 were interval 
cancers, and 26 were incidental cancers.
In the 131 re-evaluated MRI scans, lesions were consid-
ered invisible in 45 cases (34%). A minimal sign was present 
in 45 cases (34%) and lesions were visible in 41 cases (31%). 
Figure 1 presents examples of lesions in the three visibility 
categories. Of all visible lesions, 2 (5%) were re-evaluated 
as BI-RADS-3, 35 (85%) as BI-RADS-4, and 4 (10%) as BI-
RADS-5. Lesions that showed a minimal sign were scored as 
BI-RADS-2 in 22 cases (49%), and BI-RADS-3 in 23 cases 
(51%). Overall, 64 cases (49%) of prior negative MRI scans 
were scored as BI-RADS-3 or higher.
Table 2 shows the distribution of these findings in each 
subgroup. We did not observe a significant difference based 
upon the mode of cancer detection (P = 0.447). However, 
the frequency of visible findings in negative MRI scans of 
women with mammography-detected cancers was somewhat 
lower than in other categories, which is likely related to the 
simultaneous interpretation of mammograms and MRI scans 
in these cases and the fact that 8 of 13 cancers in this cat-
egory were pure DCIS. It should be noted that 5 of 16 (31%) 
interval cancers were already visible at the last scan, and 
were all scored as BI-RADS-4 or 5.
Table 2 also shows the impact of patient and imaging fac-
tors on the likelihood of false-negative MRI reports. Overall, 
the frequency of missed findings is influenced by age, the 
reason for screening, and reported image quality. Especially 
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the presence of a BRCA mutation strongly reduces the fre-
quency of visible findings in prior negative MRI scans.
Discussion
Our results show that, of 131 breast cancers with negative 
prior MRI exams retrospectively evaluated in this study, 31% 
were already visible on this negative exam. In fact, 29% of 
the 131 lesions were rated as BI-RADS-4 or BI-RADS-5 and 
should thus have been recalled based on these prior exams. 
When including cancers presenting with minimal signs, 
65% of the lesions were already recognizable on the prior 
MRI exam. Both from a learning perspective and in terms of 
liability, it is essential that these figures are available.
These results are in line with reports from Yamaguchi 
et al. [13], and Pages et al. [14] who, in smaller cohorts 
(15 and 58 patients), reported that 56 and 47% of breast 
cancers were already visible on prior MRI examinations 
and retrospectively assessed as BI-RADS-3 or higher. Both 
studies, however, only included screen-detected cancers on 
MRI. To our knowledge, this study is the first to show that 
also 31% of interval cancers and even 35% of incidental 
cancers can be identified at the last negative MRI scan.
The program sensitivity of our high-risk screening 
cohort was, as reported earlier, 89.7% [19], which is com-
parable to recent prospective studies on MRI screening in 
women at increased risk such as the Italian Hibcrit trial 
(91%) [3] and the German EVA trial (93%) [4]. Therefore, 
it is likely that our findings are applicable to all breast MRI 
screening settings. Our findings related to visibility of can-
cers in prior examinations are also similar to those found 
in mammography screening. Previous studies [7] have 
reported that up to 50% of the cancers detected in mam-
mography screening with double reading were already vis-
ible at earlier screening examinations and approximately 
half of these were suspicious.
Table 1  Time to negative MRI 
and time to cancer diagnosis (in 
months), stratified by detection 
mode and BI-RADS scores of 
prior MRI scans
In between parenthesis, the percentage of lesions in the specified category is given, except when indicated 
otherwise
a Interval cancers were defined as cancers detected in between screening rounds
b Incidental cancers were defined as cancers detected in prophylactic mastectomy specimens
MRI detect MG detect Intervala Incidentalb Overall
N (%) 76 (58) 13 (10) 16 (12) 26 (20) 131
Mean patient age in years (sd) 49.5 (11.2) 53.4 (8.3) 41.3 (9.1) 42.5 (10.6) 47.5 (11.2)
Time to last negative MRI in months (sd) 11.5 (3.0) 1.2 (3.4) 8.6 (3.1) 2.8 (3.1) 9.5 (4.5)
Histology
 IDC 49 (70) 2 (3) 15 (21) 4 (6) 70
 ILC 4 (67) 0 (0) 1 (17) 1 (17) 6
 DCIS 13 (33) 8 (21) 0 (0) 18 (46) 39
 Mixed IDC and ILC 7 (78) 0 (0) 0 (0) 2 (22) 9
 Other 3 (43) 3 (43) 0 (0) 1 (14) 7
Tumor stage at detection
 pTis 13 (33) 8 (21) 0 (0) 18 (46) 39
 pT1mic 0 (0) 0 (0) 0 (0) 1 (100) 1
 pT1a/b/c 7/22/18 (72) 3/1/0 (6) 0/1/7 (12) 2/3/1 (9) 12/27/26
 pT2 12 (71) 1 (6) 3 (18) 1 (6) 17
 pT3 1 (100) 0 (0) 0 (0) 0 (0) 1
 pT4D 1 (100) 0 (0) 0 (0) 0 (0) 1
 Recurrence 1 (33) 0 (0) 2 (67) 0 (0) 3
 Unknown 1 (25) 0 (0) 3 (75) 0 (0) 4
Nodal status at detection
 pN0 52 (60) 11 (13) 7 (8) 17 (20) 87
 pN+ 16 (67) 1 (4) 5 (21) 2 (8) 24
 Unknown 8 (40) 1 (1) 4 (20) 7 (35) 20
Visibility on prior
 Invisible 21 (47) 6 (13) 8 (18) 10 (22) 45
 Minimal sign 31 (69) 4 (9) 3 (7) 7 (16) 45
 Visible 24 (59) 3 (7) 5 (12) 9 (22) 41
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The clinical consequences of missing a cancer in an MRI 
scan obtained before prophylactic mastectomy are relatively 
minor. Most of these cancers are DCIS only. This is a rela-
tive frequent finding in prophylactic mastectomy specimen 
(approximately 5% in our institution) [20]. Since the period 
between the MRI scan and the subsequent prophylactic mas-
tectomy is usually short, it is unlikely that missing these 
lesions will alter the patients’ prognosis. Nonetheless, the 
psychological impact might be substantial and should be 
taken into account [21].
The consequences of missing breast cancers that present 
subsequently as interval cancer, on the other hand, are dire. 
These cancers usually are invasive, poorly differentiated and 
fast growing [22]. Detection of these cancers at the MRI 
examinations could still have had a significant effect on sub-
sequent prognosis and warrants investigation of methods to 
reduce false-negative reporting of MRI scans.
In the group of mammography-detected cancers, the num-
ber of visible cancers is somewhat lower than in the other 
groups, though this did not reach statistical significance. 
Fig. 1  First the subtraction 
images of a breast cancer 
invasive ductal carcinoma (IDC) 
grade 3 (a), which were rated 
as invisible in the prior MRI 
(b), second row are the images 
(c) rated as minimal sign in the 
prior image (d) also showing an 
IDC grade 3, and the last row 
are the images of the current 
MRI (e) and the visible lesion 
in the prior MRI (f) an invasive 
lobular carcinoma grade 2
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This result was expected as the examinations are in prac-
tice often reported simultaneously. The fact that we did find 
four cancers on the current MRI scan that were re-evaluated 
as visible in retrospect can therefore only be explained by 
underreporting of subtle findings on the MRI scan due to 
already significant findings on the mammogram that would 
warrant a biopsy anyway. In addition, of note is that of 
four invasive cancers in this mammography category only 
one cancer was also regarded as invisible in the consensus 
reading. The finding that the frequency of invisible in situ 
cancers is substantial (50%) underlines that, although the 
sensitivity of breast MRI is high, it is not 100%, as we are 
certain these cancers are present in the breast.
The fact that the frequency of visibility of late(r) 
detected cancers is virtually independent from the eventual 
mode of cancer detection implies that the problem should 
be sought in the evaluation of MRI scans itself. Radiolo-
gists in general may make two types of mistakes. The first 
is known as overlook error. The abnormality is simply 
not seen, and therefore cannot be classified correctly. The 
second is known as interpretation error. In this case, the 
lesion is seen but falsely interpreted as benign finding, and 
might therefore not even be reported, although the most 
evident cases of interpretation errors obviously mention 
the lesion as benign in the report [13, 14, 23, 24]. In the 
evaluation of screening breast MRI, likely both processes 
play a role. In retrospect, four cases were classified as BI-
RADS-5. It is unlikely that these lesions were seen but not 
recalled (Fig. 2). It is far more likely that these cases were 
overlooked. However, the vast majority (N = 35) of vis-
ible cases were classified in the prior exam as BI-RADS-4. 
In these cases, interpretation errors might have prevented 
recall in clinical practice. This is also supported by the 
fact that the strongest modifier of the frequency of vis-
ible lesions is the presence of a BRCA mutation (49% of 
the lesions were truly invisible in BRCA mutation carriers 
compared to 18% in others). The much higher a priori 
chance of these women to develop breast cancer compared 
to other women at increased risk [25], along with the fast 
growth of cancers in these women [26], leads to lowering 
Table 2  Visibility of lesions 
on prior negative MRI scans, 
stratified by patient and imaging 
factors
In between parenthesis, the percentage of lesions in the specified category is given, except when indicated 
otherwise
a According to the two readers in consensus in the prior MRI scan
b P value is based on Pearson Chi square test evaluating the differences between the three visibility catego-
ries (invisible, minimal sign, and visible)
c The BRCA population included also untested first-degree relatives
IQ image quality
N (%) Invisiblea (%) Minimal  signa (%) Visiblea (%) P  valueb
Overall 131 (100) 45 (34) 45 (34) 41 (31) N/A
Patient factors
 Mean age at cancer 
detection in years (sd)
47 (11.3) 44 (11.4) 46 (9.8) 52 (11.4) 0.003
 Menopausal status 0.229
  Premenopausal 60 (46) 25 (42) 17 (28) 18 (30)
  Postmenopausal 71 (54) 20 (28) 28 (39) 23 (32)
 Reason for screening 0.001
  BRCA c 70 (53) 34 (49) 23 (33) 13 (19)
  Non-BRCA 61 (47) 11 (18) 22 (36) 28 (46)
Imaging factors
 Field strength 0.895
  1.5 T 96 (73) 33 (34) 32 (33) 31 (32)
  3 T 35 (27) 12 (34) 13 (37) 10 (29)
 BPE 0.570
  Minimal 83 (63) 30 (36) 27 (33) 26 (31)
  Mild 22 (17) 5 (23) 9 (41) 8 (36)
  Moderate 12 (9) 3 (25) 4 (33) 5 (42)
  Marked 14 (11) 7 (50) 5 (36) 2 (14)
 Reported IQ 0.021
  Perfect 111 (85) 43 (39) 34 (31) 34 (31)
  Sufficient 18 (14) 1 (6) 10 (56) 7 (39)
  Bad 2 (2) 1 (50) 1 (50) 0 (0)
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the threshold for recall. In other words, women with BRCA 
mutations are recalled for lesions that would have been 
ignored in women without BRCA mutations. This might 
also explain the slightly younger age of women with invis-
ible lesions at the last negative MRI, as the BRCA popula-
tion in general is younger than the non-BRCA population.
We also observed that IQ was associated to the visibil-
ity score, with more frequent visible findings in negative 
reported MRI scans of less than perfect quality. This implies 
that striving for excellent image quality is important. When 
a scan is of inferior quality, for example due to motion 
artifacts, rescanning the patient should be considered. We 
did not detect an effect of field strength on the visibility of 
lesions in prior negative MRI scans, and therefore underline 
that adequate MRI scans can be performed at both 1.5- and 
3-T systems. BPE was not statistically related to the likeli-
hood of visibility of lesions in the last negative MRI scan. 
Nevertheless, in women with marked BPE the frequency 
of visible lesions was with 14% substantially lower than 
in other groups. We assume that very strong BPE might 
in fact sometimes obscure lesions that would otherwise be 
detected [27], though larger numbers are required for statisti-
cal analyses.
While an obvious solution to reduce misinterpretation of 
eventual cancers would be to lower the threshold for recall 
in non-BRCA mutation carriers, this cannot be straightfor-
wardly applied. We earlier analyzed the positive predictive 
value of biopsy (PPV3) in women in this cohort [19], which 
were 0.38 and 0.29 for BRCA1 and BRCA2 carriers, respec-
tively. However, in women with a positive family history 
but no BRCA mutation PPV3 was only 0.14, which implies 
that lowering the threshold for recall in these women might 
lead to unacceptable high biopsy rates for benign lesions, 
and might further jeopardize the cost-effectiveness of MRI 
screening. The optimal balance between recall and cancer 
detection for women in different risk categories has yet to 
be determined.
We acknowledge that in the consensus read a bias was 
introduced by the non-blinded fashion of the evaluation. 
Readers were aware of the breast cancer location on the 
current MRI scan, mammography, or in the excised speci-
men. While this is common practice in auditing, it has been 
postulated that this approach is too harsh and leads to more 
lesions classified as visible than what would have been the 
case in a blinded setting where cases are mixed with nor-
mal scans [28]. However, in a previous study by Gubern-
Merida et al. [29], a CAD system was used for the detec-
tion of breast cancer in a subset of 40 of the cancer cases 
that were used in the current evaluation, mixed with 120 
normal scans. At four false-positives per normal scan, the 
sensitivity of the CAD system was 0.71 and 0.31 for visible 
and minimally visible lesions in the prior negative scans, 
respectively, whereas sensitivity was 0.82 for the respective 
current scans in which the cancers were actually diagnosed. 
This implies that indeed a substantial subset of the cancers 
is at least detectable in the prior negative scans and patients 
could therefore indeed benefit from CAD-assisted reading 
or a blinded second read.
This study has some other limitations. It is a single-center 
study based upon retrospective analysis of screening data. 
However, the fact that the program sensitivity is in line with 
published prospective trials implies that the findings are 
likely generalizable to similar bi-modal screening programs 
for women at increased risk. In addition, the prospective 
reads of the scans were conducted by one of eight radiolo-
gists with a strong variability (6 months to 23 years) in expe-
rience with breast MRI, which also reflects clinical practice. 
The numbers of missed cancers are too small to assess the 
effect of experience on false-negative reporting. MRI pro-
tocols changed over time. However, all examinations were 
performed with at the time state-of-the-art equipment and 
imaging quality was in adherence with international recom-
mendations [30, 31]. Our numbers are likewise too small to 
detect whether MRI protocol changes might have influenced 
Fig. 2  An example of an 
interval cancer detected on 
ultrasound 9 months after 
prior MRI. This visible lesions 
was scored as BI-RADS 5 in 
re-evaluation; a subtraction 
image of an invasive ductal 
carcinoma grade 2 (pT1cN1mi 
(sn)) in transversal plane and b 
in coronal plane
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the frequency of visible findings in negative MRI scans over 
time.
In conclusion, our results show that almost one-third of 
breast cancers can be detected at the last reported negative 
MRI. Since this is true for both screen-detected and interval 
cancers, it is essential to find methods in order to reduce 
reading errors. As a first step, regular auditing of clinical 
practice seems to be indicated. In addition, structural double 
reading of breast MRI exams may be of value, although fur-
ther research on the added cancer detection yield is required. 
Computer-aided detection tools for cancer detection in breast 
MRI might play a significant role in the prevention of read-
ing errors in the future.
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